However, the clinical use of ∆ 9 -THC and additional synthetic agonists is often limited by their unwanted psychoactive side effects, and for this reason interest in non-psychoactive phytocannabinoids, such as CBD, has substantially increased in recent years. Interestingly CBD has no psychotropic activity and, although its very low affinity for both CB 1 and CB 2 receptors, it has been recently reported to act with unexpectedly high potency in vitro as antagonist of CB 1 receptors in the mouse vas deferens [28] and brain [29] tissues. Additionally, CBD displays inverse agonism at human CB 2 receptors [29] . Moreover, other putative CBD's molecular targets are TRPV, 5-HT 1A ,
GPR55 and PPARγ receptors (see Fig. 2 ). Interestingly CBD does not have any psychotropic activity. Besides its beneficial effects in the treatment of pain and spasticity and other CNS pathologies, several reports demonstrated that CBD possesses antiproliferative, pro-apoptotic effects and inhibits cancer cell migration, adhesion and invasion.
This review will focus on the most recent evidence regarding the efficacy of CBD in the modulation of tumorigenesis in several types of cancer. The data available so far are summarized in Table 1 and are discussed in detail in the following paragraphs.
CBD and breast cancer
In 2006 and CB 2 receptors), CBD was shown to be one of the most effective inhibitors of human breast cancer cell proliferation, being equipotent to ∆ 9 -THC and CP55940 in inhibiting respectively MDA-MB-231 and MDA-MB-436 cell growth, and resulting as the most potent inhibitor of the MDA-MB-231 cell migration. Interestingly, CBD regulated the expression of key genes involved in the control of cell proliferation and invasion through the downregulation of Id-1 expression, an inhibitor of basic helix-loop-helix transcription factors, whose overexpression in breast cancer cells is responsible for proliferation, migration and invasion. Therefore, the ability of CBD to significantly decrease Id-1 expression in breast cancer cells was associated with its efficacy in reducing tumour aggressiveness.
Four years later, the same group [32] demonstrated that the observed effect of CBD on Id-1 expression was mediated by the upregulation of the extracellular signal-regulated kinase phosphorylation (pERK). Indeed, the ERK inhibitor, U0126, partially reverted CBD-induced inhibition of proliferation and invasion as well as its effect on Id-1 expression. Besides ERK upregulation, also the production of reactive oxygen species (ROS) was shown to mediate CBDinduced effects on cell proliferation and Id-1 expression, since the use of a ROS scavenger (tocopherol) reversed the aforementioned CBD effects. Moreover, these authors demonstrated that CBD was effective in reducing the primary tumour mass and the size and number of metastatic foci in vivo.
Finally, the excellent paper of Shrivastava et al. [33] adds fresh light on the cellular mechanism through which CBD induces cell death in breast cancer cells. These authors showed that CBD induced a concentration-dependent cell death of both estrogen receptor-positive and estrogen
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receptor-negative breast cancer cells with a mechanism independent of CB 1 , CB 2 and TRPV1 receptor activation. Interestingly, the effective concentrations of CBD in tumour cells have little effect on non tumorigenic, mammary cells. Moreover, electron microscopy revealed morphologies consistent with the coexistence of autophagy and apoptosis, these events being promoted by the induction of endoplasmic reticulum (ER) stress and the inhibition of Akt/mTOR/4EBP1 signalling.
In addition, CBD-driven increase in ROS production is fundamental to induce both apoptosis and autophagy. Examining further the cellular mechanism involved in CBD-induced cell death, they found that CBD reduced mitochondrial membrane potential, triggered the translocation of the Beclin2 Interacting Protein (Bid) to the mitochondria and the release of cytochrome C to the cytosol and, ultimately, the activation of the intrinsic apoptotic pathway.
Finally, the relationship between CBD-induced apoptosis and autophagic cell death was explored by blocking each form of cell death with specific inhibitors. Caspase inhibition reduced CBDinduced apoptosis and the expression of protein markers in breast cancer cells, whereas the inhibition of autophagy enhanced apoptosis as a compensatory/alternative mechanism of cell death.
The apoptosis:autophagy ratio in CBD-induced cell death seemed to be mediated via Beclin1, a key signalling molecule in the autophagic process. CBD treatment induced the cleavage of Beclin1 and the subsequent translocation of the cleavage product to the mitochondria where it may induce apoptosis through the enhancement of cytochrome C release [34, 35] .
As a whole this work highlights the presence of a complex balance between autophagy and mitochondria-mediated apoptosis in CBD-induced breast cancer cell death and strengthens the idea that CBD can be considered as an alternative agent for breast cancer therapy. Figure 3 shows a schematic representation of the signalling pathways associated with the effect of CBD in breast cancer cell proliferation and invasion.
CBD and glioma
Accepted Article [37] reported that CBD was effective in inhibiting U87-MG and U373 human glioma cell proliferation in vitro through the induction of apoptosis. Interestingly, CBD did not affect viability of non-transformed primary glial cells [38] . When tumour xenografts were generated in immune-deficient mice, in vivo intratumoural treatment with CBD significantly reduced tumour growth [37] .
The anti-proliferative effect of CBD was cannabinoid and vanilloid receptors independent; the CB 2 receptor antagonist SR144528 reverted CBD effect, but in a weak and transient manner [37] . More important, this paper demonstrated for the first time that the anti-tumour effect of CBD involved the induction of oxidative stress, through increased early production of ROS, depletion of intracellular glutathione and increased GSH-associated enzymatic activity. Accordingly, CBD anti-proliferative effect was reversed by the anti-oxidant, tocopherol. Importantly, CBD did not induce ROS production in non-transformed primary glial cells [38] .
Among the cellular events involved in glioma cell death, CBD produced a time-dependent release of cytochrome C and activation of caspase-8, -9 and -3, suggesting the involvement of both the intrinsic and extrinsic apoptotic pathways [38] . Marcu et al. [39] later confirmed the efficacy of CBD in inhibiting the growth of multiple glioblastoma cell lines in a more potent way than ∆ 9 -THC.
Interestingly, combined treatment of ∆ 9 -THC with CBD demonstrated that CBD enhanced ∆ 9 -THC inhibitory effect on glioblastoma cell growth, but not on invasiveness [39] . In line with this, more recently Torres et al. [40] confirmed that combined treatment with CBD and ∆ 9 -THC greatly reduced several human glioma cell viability enhancing both autophagy and apoptosis and triggering
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caspase-3 activation. Moreover, combined administration of submaximal doses of CBD and ∆ 9 -THC reduced the growth of U87-MG cell-derived tumour xenografts in nude mice at a higher extent than the treatment with the individual compounds, suggesting the potential use of a combinatory therapy which would reduce the amount of the psychoactive ∆ 9 -THC.
The synergistic effect of combined therapy implied in vitro cell cycle arrest, ROS induction and apoptosis through sustained activation of caspases-3, -7 and -9, as well as specific modulation of the extracellular signal-regulated kinase, ERK [39] . These effects were not observed with either compound individually, indicating them as a prerogative of combination treatment. Differently from
Marcu's data [39] , our recent results [41] showed that, both in U87-MG and in ∆ 9 -THC-resistant T98G human glioma cell lines, CBD per se strongly down-regulates two signalling molecules crucial in tumour cell proliferation such as ERK and PI3K/Akt. In addition it inhibited the hypoxiainducible transcription factor HIF-1α, one of the most critical stimuli for cell survival, motility and tumour angiogenesis. Thus, inhibition of these three molecules appears as part of the multiple molecular targets for CBD anti-neoplastic activity [41] .
Further biochemical analysis of glioma tumour tissues excised from nude mice treated in vivo with CBD indicated a significant decrease of activity and content of 5-LOX, as well as a marked stimulation of FAAH and a decrease of AEA content [42] .
Besides cell growth, CBD reduced glioma cell migration [43] and invasiveness in a Boyden chamber test [39] , at concentrations lower than those required to inhibit cell proliferation. CBD anti-migratory effect was not antagonized by the selective cannabinoid receptor antagonists or by pretreatment with pertussis toxin, indicating no involvement of classical cannabinoid receptors and/or G i/o protein-coupled receptors.
As a whole, CBD seems to counteract glioma cell proliferation and invasion through multiple mechanisms, as summarized in In Jurkat cells, CBD exposure resulted in the activation of caspase-8, -9, and -3, the cleavage of poly(ADPribose) polymerase, and the decrease in full-length Bid, suggesting a possible cross-talk between the intrinsic and extrinsic apoptotic pathways. Moreover, exposure to CBD led to the loss of mitochondrial membrane potential and subsequent release of cytochrome C. As in other tumour cells, CBD-induced apoptosis required an increase of ROS production. Finally, CBD decreased the levels of phospho-p38 mitogen-activated protein kinase [45] , and this effect was blocked by treatment with a CB 2 -selective antagonist or ROS scavenger. In addition, CBD treatment caused a significant reduction in tumour burden and increased the level of apoptotic tumours in EL-4-bearing mice [45] .
Together, the results suggest that CBD, acting through CB 2 receptors and ROS production, may represent a novel and highly selective treatment for leukaemia. Moreover, previous evidence indicated that human leukaemias and lymphomas expressed significantly higher levels of CB 2 receptors compared to other tumour cell lines, suggesting that tumours of immune origin may be highly sensitive to the CB 2 -mediated effects of CBD [46] .
CBD and lung cancer
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Given the poor response of lung cancer to available therapy and their aggressive biological nature, a series of targets and new therapeutic strategies for their treatment are currently being investigated [47] [48] [49] [50] .
Recently, Ramer et al. [51] [52] [53] Additionally, in vivo studies in thymic aplastic nude mice revealed a significant inhibition of A549 lung metastases following CBD treatment [51] and a significant downregulation of PAI-1 protein was demonstrated in A549 xenografts of CBD-treated rats [52] .
It is worth to note that CBD decreased invasiveness in a range of therapeutically relevant concentrations (0.01 to 0.05µM), since the peak plasma concentrations of CBD in healthy Accepted Article volunteers following administration of SativexTM (1:1 ratio of ∆ 9 -THC and CBD) was reported to be between 0.01µM to 0.05µM [54] .
Together, these findings provide a novel mechanism underlying CBD anti-invasive action on human lung cancer cells and imply its use as a therapeutic option for the treatment of highly invasive cancers.
CBD and endocrine tumours
Thyroid cancer is the most common endocrine malignancy, and a work by Ligresti et al. [30] demonstrated that CBD exerted anti-proliferative effects on rat thyroid KiMol cells, transformed with the v-K-ras oncogene. This effect of CBD was associated with a cell cycle block at the G1/S phase transition, as well as the induction of apoptosis. The observation that CBD induced oxidative stress in thymocytes, EL-4 cells and splenocytes [56] substantiates the notion that, unlike monocytes, T cells both primary and immortalized are all sensitive and respond similarly to CBD, with a central role of ROS generation.
CBD and colon cancer
Colon cancer is a major cause of morbidity and mortality in Western countries. A recent paper from In the light of its safety records, these results suggest that CBD might be worthy of clinical consideration in colon cancer prevention.
CBD and angiogenesis
Angiogenesis consists in the formation of new blood vessels from pre-existing ones and represents another promising therapeutic target for cancer therapy. Collectively, cannabinoids have been demonstrated to act as anti-angiogenic factors by disposing tumour cells to decrease the production of pro-angiogenic factors and/or by direct modulation of endothelial cells [58] .
Surprisingly, so far no study investigated the effect of CBD on angiogenesis. Our data currently under publication [59] demonstrated that CBD potently inhibited HUVE cells proliferation, migration and invasion through the induction of endothelial cell cytostasis without triggering apoptosis. Interestingly, CBD also affected endothelial cell differentiation into tubular capillaries as well as the outgrowth of capillary-like structures from HUVEC spheroids in vitro. In addition, the anti-angiogenic properties of CBD were demonstrated also in vivo, using a matrigel sponge model.
These effects were associated with down-modulation of several molecules associated with angiogenesis, including MMP2, MMP9, uPA, Endothelin-1, PDGF-AA and CXCL16.
Collectively, these preliminary data demonstrate that, besides its well known pro-apoptotic antiproliferative and anti-invasive actions, CBD may also exert anti-angiogenic effects, thus further strengthening its potential application in cancer therapy.
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Conclusion and future directions
Collectively, the non-psychoactive plant-derived cannabinoid CBD exhibits pro-apoptotic and antiproliferative actions in different types of tumours and may also exert anti-migratory, anti-invasive, anti-metastatic and perhaps anti-angiogenic properties. On these bases, evidence is emerging to suggest that CBD is a potent inhibitor of both cancer growth and spreading.
Interestingly, the anticancer effect of this compound seems to be selective for cancer cells, at least in vitro, since it does not affect normal cell lines. The efficacy of CBD is linked to its ability to target multiple cellular pathways that control tumorigenesis through the modulation of different intracellular signalling depending on the cancer type considered. The most common effect of CBD is the increase in ROS production that seems to be determinant for triggering its beneficial action in all the considered cancer cell types. The role of cannabinoid/vanilloid receptors in mediating CBD effects is more controversial. In some cases (lung, leukaemia, colon) a clear contribution of these receptors has been demonstrated through the use of specific antagonists, but in other cancer types (glioma and breast) their relevance appears only marginal or absent. Besides the in vitro data, the efficacy of CBD in reducing tumour growth and, in some case, metastasization was confirmed in experimental animal models. However, the potential clinical application of CBD for cancer therapy needs some consideration. Its low toxicity is certainly a good starting point. CBD behaves as a non toxic compound; indeed oral administration of CBD 700mg/day for 6 weeks did not show any overt toxicity in humans [60] suggesting its possible exploitation for prolonged treatment. The route of administration appears more problematic since CBD oral absorption is slow and unpredictable.
However, 6 weeks of oral CBD treatment 10mg/kg/day provoked a mean plasma level of CBD between 6 and 11ng/ml (about 0.036µM) [61] that did not differ significantly over the 6 weeks of administration. Interestingly, this range of concentration was demonstrated to be active in inhibiting lung cancer cell invasion [52, 53] thus suggesting that in some cases the oral route could be the Moreover, oromucosal administration may represent a first choice in presence of nausea and vomiting. Finally, the use of CBD/Sativex can be suggested in combination with classical chemotherapeutic agents to check for the presence of a synergistic effect that might potentially allow clinical chemotherapeutic dose reduction, thereby reducing toxicity while maintaining efficacy. In the light of its safety records and considering that CBD is already currently used in patients with multiple sclerosis, the findings here summarized suggest that CBD might be worthy of clinical consideration for cancer therapy.
Nomenclature
The drug/molecular target nomenclature conforms top the BJP's Guide to Receptors and Channels
[63]. 
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